Photo from Earle Burgess/LinkedIn
Jul 25, 2024, 08:49
Earle Burgess: Another interesting new drug in development for metastatic castrate resistant prostate cancer
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health, Levine Cancer Institute, shared on LinkedIn:
”ARV-766: another interesting new drug in development for metastatic castrate resistant prostate cancer (mCRPC) with promising early phase data presented at ASCO24.
ARV-766 is an AR ‘PROTAC,’ a molecule that enhances degradation of the androgen receptor (AR) inside of prostate cancer cells.
20-25% of patients with mCRPC have tumor mutations in the AR ligand binding domain (LBD).
In a small cohort of heavily pretreated mCRPC patients whose tumors had mutations in the AR LBD, ARV-766 led to a 50% decrease in PSA levels in 43% of patients.
Impressive preliminary data for this patient population.”
Source: Earle Burgess/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 26, 2024, 18:39
Oct 26, 2024, 18:30
Oct 26, 2024, 18:28
Oct 26, 2024, 18:16
Oct 26, 2024, 18:03